What's Going On With Recursion Pharmaceuticals Stock?
Recursion Pharmaceuticals Says Potential Advanced Solid Tumor Treatment Well Tolerated
Express News | Recursion Pharmaceuticals Inc: Plans to Continue Monotherapy Dose Escalation and Initiate Combination Studies in 1H 2025
Express News | Recursion Pharmaceuticals Inc: REC-617 Well-Tolerated With No Discontinuations Due to Adverse Events
Express News | Recursion Pharmaceuticals: 4 Patients Demonstrated a Best Response of Stable Disease for up to 6 Months of Treatment
Express News | Recursion Pharmaceuticals Inc: Confirmed Partial Response in Platinum-Resistant Ovarian Cancer Patient
Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability
Express News | Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class Cdk7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability
Recursion Pharmaceuticals Insider Sold Shares Worth $285,600, According to a Recent SEC Filing
Ulta Beauty Posts Upbeat Results, Joins Asana, Lululemon, Hewlett Packard Enterprise And Other Big Stocks Moving Higher On Friday
Jim Cramer on Recursion Pharmaceuticals, Inc. (RXRX): 'It Is Worthwhile Speculation'
10 Health Care Stocks Whale Activity In Today's Session
Recursion Pharmaceuticals CFO Ben Taylor to Join Exscientia
Recursion Pharmaceuticals (RXRX) Bold Acquisition Makes It a Leader in AI Drug Discovery
Recursion Announces First Patient Dosed In Phase 1/2 Clinical Study Of REC-1245, A RBM39 Degrader For Biomarker-Enriched Solid Tumors And Lymphoma
Express News | Recursion Announces First Patient Dosed in Phase 1/2 Clinical Study of REC-1245, a Potential First-in-Class, Rbm39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma
Nvidia Bought 6 Artificial Intelligence (AI) Stocks, but This 1 Has Soared the Most
XPeng, NovoCure, Merus, Gap And Other Big Stocks Moving Higher On Monday
Following nvidia to invest in ai? These three small cap ai stocks are worth attention.
As the current leader in AI technology, nvidia also participates in practical application scenarios of AI+ through investment and shareholding.
(RXRX) - Analyzing Recursion Pharmaceuticals's Short Interest